Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase I/II trial to study the effectiveness of CC-1088 in treating patients who have chronic lymphocytic leukemia that has not responded to previous therapy.
|Study Design:||Primary Purpose: Treatment|
|Official Title:||CC-1088 Therapy for Chronic Lymphocytic Leukemia: A Phase I/II Trial|
|Study Start Date:||August 1999|
|Study Completion Date:||July 2005|
|Primary Completion Date:||July 2005 (Final data collection date for primary outcome measure)|
OBJECTIVES: I. Determine the toxicity of CC-1088 in patients with refractory, progressive, B-cell chronic lymphocytic leukemia. II. Determine the response rate to this treatment in these patients.
OUTLINE: Patients receive oral CC-1088 three times a day for 28 days. Treatment continues in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 11-20 patients will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00006097
|United States, Massachusetts|
|Boston Medical Center|
|Boston, Massachusetts, United States, 02118|
|Study Chair:||Timothy J. Ernst, MD||Boston Medical Center|